Dyadic (AMEX:DIL)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Dyadic Charts. Click Here for more Dyadic Charts.](/p.php?pid=staticchart&s=A%5EDIL&p=8&t=15)
Dyadic International, Inc. (AMEX:DIL), a biotechnology company,
announced today that it was granted U.S. patent 7,122,330,
"High-Throughput Screening of Expressed DNA Libraries in Filamentous
Fungi," by the U.S. Patent and Trademark Office.
Dr. Glenn Nedwin, Dyadic's Chief Scientific Officer, Executive Vice
President and President of Dyadic's Biosciences Business, said, "This
patent protects Dyadic's novel technology for robotic screening in
filamentous fungi using our proprietary C1 Host Technology platform.
With broad claims covering a number of other industrially relevant
fungi, including Trichoderma and Aspergillus, we believe
the patent also validates Dyadic's 'one stop shop' model where gene
discovery and improvement, gene expression, and product manufacturing in
quantities from 1 ml to 150,000 liters can all be performed in the same
host organism. We believe that this, in turn, should improve the odds of
identifying potentially useful proteins, shorten R&D development
timelines, and reduce development costs."
Dr. Nedwin added, "We already are using this patented technology in
Dyadic's programs to identify optimal enzymes and enzyme mixtures to
increase the efficiency of extracting sugars from renewable biomass, a
critical step in the production of low-cost cellulosic ethanol,
plastics, polymers and other products now derived from petroleum. We
also are using our technology to expand the pipeline of new, more
effective and lower cost enzymes used in the pulp & paper, textile,
animal feed and other industrial processes, and are developing the
technology to facilitate the rapid, low-cost screening of antibodies and
other proteins for therapeutic applications. We believe that the unique
capabilities of our patented technology give us an important advantage
in the development of cost-effective commercial products in each of our
target markets."
About Dyadic
Dyadic International, Inc., based in Jupiter, Florida, with operations
in the United States of America, Hong Kong and mainland China, Poland
and The Netherlands, is engaged in the development, manufacture and sale
of biological products using a number of proprietary fungal strains to
produce enzymes and other biomaterials, principally focused on a system
for protein production based on the patented Chrysosporium lucknowense
fungus, known as C1. Dyadic is applying its technologies to produce
enzymes for use in converting various agricultural products (e.g. corn)
and waste products (e.g. switch grass, wheat straw, sugar cane bagasse,
etc.) into fermentable sugars, which can then be used in the production
of traditional and cellulosic ethanol as well as other products
currently derived from petroleum. Dyadic's C1 technology also is being
developed to facilitate the discovery, development and large-scale
production of human antibodies and other high-value therapeutic
proteins. Dyadic currently sells more than 45 liquid and dry enzyme
products to more than 200 industrial customers in approximately 50
countries for the textile, pulp & paper, animal feed, alcohol, starch,
and food and beverage industries.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking
statements involve risks and uncertainties that could cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of charge
on the SEC's web site at http://www.sec.gov,
including our Annual Report on Form 10-KSB for the year ended December
31, 2005, and our subsequent filings with the SEC. Except as
required by law, we expressly disclaim any intent or obligation to
update any forward-looking statements.
Dyadic International, Inc. (AMEX:DIL), a biotechnology company,
announced today that it was granted U.S. patent 7,122,330,
"High-Throughput Screening of Expressed DNA Libraries in Filamentous
Fungi," by the U.S. Patent and Trademark Office.
Dr. Glenn Nedwin, Dyadic's Chief Scientific Officer, Executive
Vice President and President of Dyadic's Biosciences Business, said,
"This patent protects Dyadic's novel technology for robotic screening
in filamentous fungi using our proprietary C1 Host Technology
platform. With broad claims covering a number of other industrially
relevant fungi, including Trichoderma and Aspergillus, we believe the
patent also validates Dyadic's 'one stop shop' model where gene
discovery and improvement, gene expression, and product manufacturing
in quantities from 1 ml to 150,000 liters can all be performed in the
same host organism. We believe that this, in turn, should improve the
odds of identifying potentially useful proteins, shorten R&D
development timelines, and reduce development costs."
Dr. Nedwin added, "We already are using this patented technology
in Dyadic's programs to identify optimal enzymes and enzyme mixtures
to increase the efficiency of extracting sugars from renewable
biomass, a critical step in the production of low-cost cellulosic
ethanol, plastics, polymers and other products now derived from
petroleum. We also are using our technology to expand the pipeline of
new, more effective and lower cost enzymes used in the pulp & paper,
textile, animal feed and other industrial processes, and are
developing the technology to facilitate the rapid, low-cost screening
of antibodies and other proteins for therapeutic applications. We
believe that the unique capabilities of our patented technology give
us an important advantage in the development of cost-effective
commercial products in each of our target markets."
About Dyadic
Dyadic International, Inc., based in Jupiter, Florida, with
operations in the United States of America, Hong Kong and mainland
China, Poland and The Netherlands, is engaged in the development,
manufacture and sale of biological products using a number of
proprietary fungal strains to produce enzymes and other biomaterials,
principally focused on a system for protein production based on the
patented Chrysosporium lucknowense fungus, known as C1. Dyadic is
applying its technologies to produce enzymes for use in converting
various agricultural products (e.g. corn) and waste products (e.g.
switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable
sugars, which can then be used in the production of traditional and
cellulosic ethanol as well as other products currently derived from
petroleum. Dyadic's C1 technology also is being developed to
facilitate the discovery, development and large-scale production of
human antibodies and other high-value therapeutic proteins. Dyadic
currently sells more than 45 liquid and dry enzyme products to more
than 200 industrial customers in approximately 50 countries for the
textile, pulp & paper, animal feed, alcohol, starch, and food and
beverage industries.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements involve
risks and uncertainties that could cause our actual results,
performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of charge
on the SEC's web site at http://www.sec.gov, including our Annual
Report on Form 10-KSB for the year ended December 31, 2005, and our
subsequent filings with the SEC. Except as required by law, we
expressly disclaim any intent or obligation to update any
forward-looking statements.